PROBIOTIX HEALTH LS-05 (X90) - Total Assets
Based on the latest financial reports, PROBIOTIX HEALTH LS-05 (X90) holds total assets worth €2.38 Million EUR (≈ $2.78 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can PROBIOTIX HEALTH LS-05 service its debt to assess how comfortably operating cash covers total debt obligations.
PROBIOTIX HEALTH LS-05 - Total Assets Trend (2022–2024)
This chart illustrates how PROBIOTIX HEALTH LS-05's total assets have evolved over time, based on quarterly financial data. See PROBIOTIX HEALTH LS-05 (X90) net assets for net asset value and shareholders' equity analysis.
PROBIOTIX HEALTH LS-05 - Asset Composition Analysis
Current Asset Composition (December 2024)
PROBIOTIX HEALTH LS-05's total assets of €2.38 Million consist of 88.8% current assets and 11.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 75.6% |
| Accounts Receivable | €141.00K | 6.5% |
| Inventory | €31.00K | 1.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €239.00K | 11.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how PROBIOTIX HEALTH LS-05's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PROBIOTIX HEALTH LS-05 stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PROBIOTIX HEALTH LS-05's current assets represent 88.8% of total assets in 2024, an increase from 86.5% in 2022.
- Cash Position: Cash and equivalents constituted 75.6% of total assets in 2024, up from 65.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 13.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 11.0% of total assets.
PROBIOTIX HEALTH LS-05 Competitors by Total Assets
Key competitors of PROBIOTIX HEALTH LS-05 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
PROBIOTIX HEALTH LS-05 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.02 | 3.06 | 3.06 |
| Quick Ratio | 3.99 | 2.88 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.62 Million | €1.07 Million | €1.07 Million |
PROBIOTIX HEALTH LS-05 - Advanced Valuation Insights
This section examines the relationship between PROBIOTIX HEALTH LS-05's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.62 |
| Latest Market Cap to Assets Ratio | 5.95 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | €2.18 Million |
| Market Capitalization | $12.94 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values PROBIOTIX HEALTH LS-05's assets at a significant premium (5.95x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: PROBIOTIX HEALTH LS-05's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for PROBIOTIX HEALTH LS-05 (2022–2024)
The table below shows the annual total assets of PROBIOTIX HEALTH LS-05 from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €2.18 Million ≈ $2.55 Million |
+0.23% |
| 2023-12-31 | €2.17 Million ≈ $2.54 Million |
-7.26% |
| 2022-12-31 | €2.34 Million ≈ $2.74 Million |
-- |
About PROBIOTIX HEALTH LS-05
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and … Read more